--- title: "Is Pfizer (PFE) Stock Too Pricey for Its Earnings Outlook?" type: "News" locale: "en" url: "https://longbridge.com/en/news/296706606.md" description: "Pfizer (PFE) appears overvalued with a P/E of 36.9x, exceeding its tailored fair multiple of 24.7x and the industry average of 16.8x. Despite a 16.1% annual return driven by pipeline progress in mRNA and cancer therapies, legal risks like the Chantix settlement persist. Simply Wall St's valuation checks yield mixed signals, suggesting recent gains may already price in optimistic earnings assumptions." datetime: "2026-08-23T15:55:03.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296706606.md) - [en](https://longbridge.com/en/news/296706606.md) - [zh-HK](https://longbridge.com/zh-HK/news/296706606.md) generator: "portal-rs" --- # Is Pfizer (PFE) Stock Too Pricey for Its Earnings Outlook? Pfizer stock has returned 16.1% over the past year after a weaker five year stretch, while the valuation checks and market multiples now point to a mixed picture rather than a clear bargain. - The share price is still down 21.5% over 5 years, which suggests longer term holders have not yet fully recovered their losses despite the recent rebound. - Regulatory progress on the Lyme disease vaccine candidate and broader interest in mRNA and cancer antibody conjugate therapies can support sentiment, while legal and product risk, highlighted by the recent Chantix settlement, may weigh on how much investors are willing to pay for Pfizer's future earnings. - Pfizer scores 3 out of 6 on Simply Wall St's valuation checks, which is a mixed signal rather than a clear green light that the stock is cheap on the usual metrics 3. The issue now is whether the recent share price recovery has already reflected most of Pfizer's potential, or if there is still room for upside based on what investors are paying for today. Find out why Pfizer's 16.1% return over the last year is lagging behind its peers. ### Does Pfizer Look Pricey on Earnings? P/E is a useful quick check for Pfizer because investors often focus on earnings power for large, mature pharmaceutical companies. Pfizer currently trades on a P/E of 36.9x, compared with an industry average of 16.8x for pharmaceuticals and a peer group average of 56.5x. That puts the stock at a premium to the broader sector, even if it is below the peer set that includes higher multiple companies. The tailored fair P/E ratio for Pfizer is 24.7x, which reflects what investors might typically pay given its earnings profile, business mix and risk factors. The current 36.9x is well above this level, which suggests the market is already pricing in a generous view of future earnings. Despite the recent boost in sentiment from progress on the Lyme disease vaccine candidate and interest in mRNA and cancer antibody conjugate therapies, the earnings multiple still appears high relative to this fair level. **On this P/E multiple, Pfizer stock appears overvalued compared with what the model indicates could be a more balanced price.** NYSE:PFE P/E Ratio as at Aug 2026 See what the numbers say about this price — find out in our valuation breakdown. ### The Pfizer Narrative: What Would Justify Today's Price? Simply Wall St Narratives pick up where the Pfizer valuation puzzle leaves off. They explain which assumptions about Pfizer's future growth, margins and earnings would need to hold for the stock to be worth materially more or less than today's price, and they sit on Simply Wall St's Community page. Rather than a single multiple or model output, each one lays out its own fair value assumptions so you can later compare them with the company’s reported results. The community is split on Pfizer stock, with one group leaning into the pipeline story while the other worries about how the patent and COVID reset plays out. **Bull case: roughly fairly valued** > *"Robust expansion of Pfizer's late-stage pipeline, especially in oncology and rare diseases, with multiple high-potential launches and label expansions (e.g., Elrexfio in multiple myeloma, SV in non-small cell lung cancer, advanced ADC portfolio, and pipeline vaccines) stands to drive sustained long-term revenue and earnings growth by addressing rising global demand for innovative therapies as the population ages…"* **Read the full Bull Case** to see why Pfizer could be undervalued **Bear case: roughly fairly valued** > *"O 'patent cliff' maior se concentra entre 2026-2030, com até US$ 17-18 bilhões em receitas anuais em risco de drogas como Eliquis, Vyndaqel, Prevnar, Ibrance e Xtandi enfrentando genéricos…"* **Read the full Bear Case** to see why Pfizer could be overvalued Do you think there's more to the story for Pfizer? Head over to our Community to see what others are saying! ### The Bottom Line Pfizer looks overvalued on its current P/E relative to both its tailored fair multiple and the broader pharmaceuticals sector, which means the recent recovery already bakes in optimistic assumptions. With valuation checks sending a mixed signal, the key question is whether earnings from its pipeline and newer platforms can eventually support this richer multiple without relying on another sentiment surge. For you as an investor, the crux is whether Pfizer can translate its late stage drugs and vaccines into durable earnings that justify paying a premium today, despite ongoing legal and product risk. *This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.* ### **New:** Manage All Your Stock Portfolios in One Place We've created the **ultimate portfolio companion** for stock investors, **and it's free.** • Connect an unlimited number of Portfolios and see your total in one currency • Be alerted to new Warning Signs or Risks via email or mobile • Track the Fair Value of your stocks Try a Demo Portfolio for Free ### Related Stocks - [PFE.US](https://longbridge.com/en/quote/PFE.US.md) ## Related News & Research - [Prediction: This Is Where Pfizer Stock Will Be in 2030](https://longbridge.com/en/news/296683959.md) - [Pfizer Inc. $PFE Shares Bought by Farther Finance Advisors LLC](https://longbridge.com/en/news/296071335.md) - [Moderna Just Doubled on a Massive Cancer Breakthrough. Here’s Why MRNA Stock Isn’t a Buy Yet.](https://longbridge.com/en/news/296643850.md) - [EMA validates Pfizer and Valneva’s Lyme disease vaccine](https://longbridge.com/en/news/296088348.md) - [05:28 ETChina's Personalized mRNA Cancer Therapy Sector Accelerates: How Far Is It From a "DeepSeek Moment"?](https://longbridge.com/en/news/296596921.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**